Brand Name(s):Zejula

Indication:Cancer- maintenance treatment of adult patients with platinum-sensitive relapsed high grade serous epithelial ovarian, fallopian tube, or primary peritoneal



Review Date:Mar-26

NICE recommends niraparib for use within the Cancer Drugs Fund as an option for maintenance treatment of advanced (FIGO stages 3 and 4) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer after response to first-line platinum-based chemotherapy in adults.

Blood pressure should be monitored at least weekly for the first 2 months, then monthly for the first year and periodically thereafter, as there have been reports of severe hypertension (including hypertensive crisis) and PRES as early as within the first month of treatment.